We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Moderna (MRNA - Free Report) closed at $54.26 in the latest trading session, marking a +2.69% move from the prior day. This change outpaced the S&P 500's 0.8% gain on the day. Meanwhile, the Dow lost 0.15%, and the Nasdaq, a tech-heavy index, added 1.6%.
The biotechnology company's stock has dropped by 2.02% in the past month, falling short of the Medical sector's loss of 0.77% and the S&P 500's gain of 5.15%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. On that day, Moderna is projected to report earnings of -$2.28 per share, which would represent year-over-year growth of 9.52%. Meanwhile, our latest consensus estimate is calling for revenue of $229.83 million, up 112.81% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$7.01 per share and revenue of $2.08 billion, indicating changes of +3.44% and +7.13%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.59% decrease. Currently, Moderna is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 95, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
Moderna (MRNA - Free Report) closed at $54.26 in the latest trading session, marking a +2.69% move from the prior day. This change outpaced the S&P 500's 0.8% gain on the day. Meanwhile, the Dow lost 0.15%, and the Nasdaq, a tech-heavy index, added 1.6%.
The biotechnology company's stock has dropped by 2.02% in the past month, falling short of the Medical sector's loss of 0.77% and the S&P 500's gain of 5.15%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. On that day, Moderna is projected to report earnings of -$2.28 per share, which would represent year-over-year growth of 9.52%. Meanwhile, our latest consensus estimate is calling for revenue of $229.83 million, up 112.81% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$7.01 per share and revenue of $2.08 billion, indicating changes of +3.44% and +7.13%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.59% decrease. Currently, Moderna is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 95, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.